• NEWS . 08 Jun 2020
  • Ticagrelor linked to low bleeding and CV events in NSTEMI patients

  • In a phase IV, single-arm study of Taiwanese patients with non ST-segment elevation myocardial infarction (NSTEMI), ticagrelor for up to 1 year was associated with a low rate of major bleeding events and a low incidence of major cardiovascular (CV) events. 

    In the study, the safety of ticagrelor was evaluated according to adverse events (AEs), serious AEs (SAEs) and PLATO-defined bleeding events, as well the cumulative incidence of major CV events (CV death, myocardial infarction and stroke). 

    Of the 108 patients included across 13 centres, 32 (29.6%) had ≥1 PLATO-defined bleeding event. Seven (6.5%) patients experienced major bleeding events with a Kaplan–Meier (KM) estimated event risk of 7.1% (95% confidence interval [CI], 3.4–14.4). Of these, four (3.7%) had life-threatening bleeding and three (2.8%) had other major bleeding. No PLATO-defined fatal bleeding was observed. SAEs were reported in 23 (21.3%) patients, whereas six (5.6%) patients had major CV events during the 1-year follow-up period (KM-estimated event risk 5.6%; 95% Cl, 2.6–12.0).

    The researchers also added that the overall safety of ticagrelor was consistent with its established safety profile. 

    Mar GY, et al. Safety and cumulative incidence of major cardiovascular events with ticagrelor in Taiwanese patients with non-ST-segment elevation myocardial infarction: A 12-month, prospective, phase IV, multicenter, single-arm study. Acta Cardiol Sin 2020;36:195–206.